An important aim in cancer therapy is the development of drug carriers to successfully carry chemotherapeutics to tumor cells while reducing chemotherapy induced severe side effects. Mesoporous silica nanoparticles (MSN) represent ideal nanodevices for localized drug delivery thanks to their peculiar structural properties and biocompatibility. MSNs with their large surface areas and easy surface functionalization allow to encapsulate diverse therapeutic agents and to bind ligands for targeting biomarkers overexpressed on cancer cells (1). In this study, a MSN-based nanocarrier (FOL-MSNBTZ) loaded with the antineoplastic drug bortezomib (BTZ) and bearing folic acid (FOL) as targeting function has been designed and develope
Mesoporous silica-based nanocarrier for targeted cancer therapy
Leggio A.;De Santo;Fava M.;Morelli C.;Pasqua L.
2021-01-01
Abstract
An important aim in cancer therapy is the development of drug carriers to successfully carry chemotherapeutics to tumor cells while reducing chemotherapy induced severe side effects. Mesoporous silica nanoparticles (MSN) represent ideal nanodevices for localized drug delivery thanks to their peculiar structural properties and biocompatibility. MSNs with their large surface areas and easy surface functionalization allow to encapsulate diverse therapeutic agents and to bind ligands for targeting biomarkers overexpressed on cancer cells (1). In this study, a MSN-based nanocarrier (FOL-MSNBTZ) loaded with the antineoplastic drug bortezomib (BTZ) and bearing folic acid (FOL) as targeting function has been designed and developeI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
